3637-58-9

Usage

Uses

Used in Organic Synthesis:
CYCLOHEXYLMETHYL-HYDRAZINE HYDROCHLORIDE is used as a reagent in organic synthesis for its ability to participate in various organic reactions, leading to the formation of a wide array of products.
Used in Pharmaceutical Research:
In pharmaceutical research, CYCLOHEXYLMETHYL-HYDRAZINE HYDROCHLORIDE is utilized as a reducing agent, playing a crucial role in the development of new pharmaceutical compounds.
Used in the Production of Pharmaceuticals:
CYCLOHEXYLMETHYL-HYDRAZINE HYDROCHLORIDE is used as a key component in the manufacturing process of certain pharmaceuticals, contributing to their therapeutic properties.
Used in the Production of Agrochemicals:
CYCLOHEXYLMETHYL-HYDRAZINE HYDROCHLORIDE is also employed in the production of agrochemicals, where it may enhance the effectiveness of these products in agricultural applications.
Used in Neurological Disorder Treatment:
CYCLOHEXYLMETHYL-HYDRAZINE HYDROCHLORIDE has potential applications in the treatment of neurological disorders, capitalizing on its ability to interact with specific biological targets relevant to these conditions.
Used in Cancer Treatment:
With its potential to target biological mechanisms involved in cancer, CYCLOHEXYLMETHYL-HYDRAZINE HYDROCHLORIDE is being explored for its use in cancer treatment, offering a novel approach to managing this disease.

Upstream product

• 1608125-58-1 tert-butyl-1-(cyclohexylmethyl)-2-(propan-2-ylidene)hydrazine carboxylate 

Downstream Products

• 382176-88-7 1-(cyclohexylmethyl)-3-methyl-1H-pyrazol-5(4H)-one 
• 1608125-59-2 1-(cyclohexylmethyl)-3-methyl-5-((3-methyl-1-phenyl-1H-pyrazol-5-yl)methoxy)-1H-pyrazole 
• 1487461-37-9 ethyl 1-(cyclohexylmethyl)-5-hydroxy-1H-pyrazole-3-carboxylate 

Relevant academic research and scientific papers

PYRAZOLE DERIVATIVES AND THEIR USES THEREOF

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias

Idiopathic or immune thrombocytopenia (ITP) is a serious clinical disorder involving the destruction of platelets by macrophages. Small molecule therapeutics are highly sought after to ease the burden on current therapies derived from human sources. Earlier, we discovered that dimers of five-membered heterocycles exhibited potential to inhibit phagocytosis of human RBCs by macrophages. Here, we reveal a structure-activity relationship of the bis-pyrazole class of molecules with -C-C-, -C-N- and -C-O- linkers, and their evaluation as inhibitors of phagocytosis of antibody-opsonized human RBCs as potential therapeutics for ITP. We have uncovered three potential candidates, 37, 47 and 50, all carrying a different linker connecting the two pyrazole moieties. Among these compounds, hydroxypyrazole derivative 50 is the most potent compound with an IC50 of 14 ± 9 μM for inhibiting the phagocytosis of antibody-opsonized human RBCs by macrophages. None of the compounds exhibited significant potential to induce apoptosis in peripheral blood mononuclear cells (PBMCs). Current study has revealed specific functional features, such as up to 2-atom spacer arm and alkyl substitution at one of the N1 positions of the bivalent pyrazole core to be important for the inhibitory activity.